Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* Aged between 18 and 70 years~* Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment~* Willing to adhere to the study protocol~Exclusion Criteria:~* Being pregnant~* Acute cytolysis in the last three months before enrollment~* Any vaccination before or during the month preceding enrollment~* Any Intolerance or allergy to any component of the vaccine~* Ongoing opportunistic infection~* Hematological disorder~* Cancer~* Unexplained fever the week before enrollment~* Immunosuppressive or immunomodulating treatment in the last six months~* Liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
- 20 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6

Based on this trial design, predict the completion outcome and termination type (if applicable).